Group 1 - The core index of the CSI 1000 Healthcare Index closed at 14247.06 points, with a one-month increase of 7.51%, a three-month increase of 25.91%, and a year-to-date increase of 32.65% [1] - The CSI 1000 Index series selects liquid and representative securities from each industry to form ten industry indices, providing diversified investment targets for investors [1] - The top ten holdings in the CSI 1000 Healthcare Index include: Borui Pharmaceutical (3.76%), Tonghua Golden Horse (2.77%), Zai Jian Pharmaceutical (2.39%), Furuide Co. (1.96%), Zhongsheng Pharmaceutical (1.83%), Rongchang Bio (1.69%), Zhaoyan New Drug (1.69%), Zuoli Pharmaceutical (1.62%), Anke Bio (1.61%), and Yipin Hong (1.46%) [1] Group 2 - The market share of the CSI 1000 Healthcare Index holdings is 54.86% from the Shanghai Stock Exchange and 45.14% from the Shenzhen Stock Exchange [1] - The industry composition of the CSI 1000 Healthcare Index includes: Chemical drugs (34.72%), Medical devices (20.46%), Traditional Chinese medicine (16.77%), Biological drugs (14.77%), Medical commerce and services (7.27%), and Pharmaceutical and biotechnology services (6.01%) [2] - The index sample is adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December, and can be adjusted temporarily under special circumstances [2]

Group 1 - The core viewpoint of the article highlights the significant performance of the China Securities Hong Kong 100 Healthcare Index, which has seen a remarkable increase of 21.00% in the past month, 52.68% in the past three months, and 95.84% year-to-date [1] - The index is categorized based on the China Securities industry classification standards, with a base date of December 31, 2004, and a base point of 1000.0 [1] - The index is fully composed of securities listed on the Hong Kong Stock Exchange, with the chemical drugs sector accounting for 54.75%, biopharmaceuticals for 18.73%, pharmaceutical and biotechnology services for 14.45%, and medical commerce and services for 12.07% [1] Group 2 - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments under special circumstances [2] - Adjustments to the index samples occur in response to changes in the parent index, special events affecting industry classification, or the delisting of sample companies [2]

Core Viewpoint - The China Securities Hong Kong 100 Pharmaceutical and Health Index has shown significant growth, with a year-to-date increase of 89.44% and a recent one-month increase of 20.84% [1]. Group 1: Index Performance - The China Securities Hong Kong 100 Pharmaceutical and Health Index reported a value of 1095.17 points [1]. - The index has increased by 44.95% over the past three months [1]. - The index is based on a sample of securities classified according to the China Securities industry classification standards, with a base date of December 31, 2004, set at 1000.0 points [1]. Group 2: Index Composition - The index is fully composed of securities listed on the Hong Kong Stock Exchange, with a 100.00% allocation [1]. - The composition by industry includes: - Chemical drugs: 55.11% - Biological drugs: 18.62% - Pharmaceutical and biotechnology services: 14.56% - Medical commerce and services: 11.71% [1]. Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]. - Adjustments occur in response to changes in the parent index, special events affecting industry classification, or the delisting of sample companies [2].

Core Viewpoint - The China Securities Hong Kong 100 Pharmaceutical and Health Index has shown significant growth, with a 22.21% increase over the past month, 41.09% over the past three months, and a remarkable 96.31% year-to-date [1]. Group 1: Index Performance - The China Securities Hong Kong 100 Pharmaceutical and Health Index is currently at 1134.87 points [1]. - The index is classified based on the China Securities Industry Classification Standard, with a base date of December 31, 2004, set at 1000.0 points [1]. Group 2: Market Composition - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100.00% allocation [1]. - The industry composition of the index includes: - Chemical drugs: 54.47% - Biological drugs: 19.42% - Pharmaceutical and biotechnology services: 14.91% - Medical commerce and services: 11.20% [1]. Group 3: Index Adjustment Mechanism - The index samples are adjusted biannually, specifically on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with provisions for temporary adjustments under special circumstances [2].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme has shown significant growth, with a year-to-date increase of 58.75% [1] Group 1: Index Performance - The index rose by 2.58% to 1088.62 points, with a trading volume of 19.47 billion [1] - Over the past month, the index has increased by 16.48%, and over the last three months, it has risen by 31.51% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (15.03%), JD Health (10.75%), and WuXi AppTec (6.59%) [1] Group 3: Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange [2] - The sector breakdown of the index includes: Pharmaceuticals and Biotechnology Services (33.30%), Medical Services (32.85%), Medical Devices (12.81%), Chemical Drugs (12.34%), and Biological Drugs (8.70%) [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special adjustments made under certain circumstances [2]

Group 1 - The core viewpoint of the news is that the China Securities Hong Kong 100 Pharmaceutical and Health Index has shown significant growth, with a year-to-date increase of 90.32% [1] - The index has risen by 18.48% in the past month and 36.79% in the last three months, indicating strong performance in the pharmaceutical sector [1] - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a base date of December 31, 2004, and a base point of 1000.0 [1] Group 2 - The index sample is adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, but can be temporarily modified under special circumstances [2] - Adjustments to the index sample occur in response to events such as delistings, mergers, or changes in industry classification [2]

Core Insights - The CSI 1000 Healthcare Index has shown significant growth, with a 13.89% increase over the past month, 24.30% over the last three months, and 27.10% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 13651.50 points [1] - The index is designed to provide a diversified investment option by selecting liquid and representative securities from each industry [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Borui Pharmaceutical (3.51%) - Tonghua Golden Horse (2.65%) - Zai Lab (2.51%) - Zhongsheng Pharmaceutical (1.75%) - Zhaoyan New Drug (1.70%) - Anke Biotechnology (1.66%) - Yipinhong (1.63%) - Zuoli Pharmaceutical (1.59%) - Furuide (1.39%) - Dongcheng Pharmaceutical (1.33%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.62%, while the Shenzhen Stock Exchange accounts for 44.38% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 36.28% - Medical devices: 19.30% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.30% - Medical commerce and services: 7.16% - Pharmaceutical and biotechnology services: 5.94% [2] Group 4: Sample Adjustment - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments [2] - When a sample company is delisted, it will be removed from the index, and any mergers, acquisitions, or splits will be handled according to maintenance guidelines [2]

Core Points - The China Securities Hong Kong 100 Pharmaceutical and Health Index (H100 Pharmaceutical, L11185) reported a significant increase, with a 20.90% rise over the past month, 36.74% over the past three months, and an impressive 88.77% year-to-date [1] Group 1 - The index is classified according to the China Securities industry classification standards, with all securities in each industry forming the corresponding industry index sample [1] - The base date for the index is December 31, 2004, with a base point of 1000.0 [1] - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100.00% allocation [1] Group 2 - The composition of the H100 Pharmaceutical Index includes 54.55% in chemical drugs, 19.02% in biological drugs, 15.26% in pharmaceutical and biotechnology services, and 11.18% in medical commerce and services [1] - The index sample is adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Core Points - The CSI Biopharmaceutical Theme 50 Index (CSI Pharma 50) has shown significant growth, with an increase of 8.88% over the past month, 15.61% over the past three months, and 12.91% year-to-date [1] - The index comprises 50 listed companies in the biopharmaceutical sector that exhibit high profitability, strong cash flow, and innovation capabilities, reflecting the overall performance of representative companies in this theme [1] Index Composition - The top ten weighted companies in the CSI Pharma 50 Index are: WuXi AppTec (17.54%), Hengrui Medicine (15.25%), Mindray Medical (11.6%), Aier Eye Hospital (4.96%), Kelun Pharmaceutical (3.32%), New Horizon (2.9%), Changchun High-tech (2.83%), Aimeike (2.28%), Huatai Medical (2.12%), and Baillie Gifford (2.05%) [1] - The index is evenly split between the Shenzhen Stock Exchange and the Shanghai Stock Exchange, each accounting for 50% of the holdings [1] Industry Breakdown - The industry composition of the CSI Pharma 50 Index is as follows: Chemical drugs (31.34%), Medical devices (25.53%), Pharmaceutical and biotechnology services (19.38%), Biopharmaceuticals (15.64%), Medical commerce and services (4.96%), and Traditional Chinese medicine (3.14%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]